Albireo licences Asian rights for Elobixibat to Ajimoto - 04-Apr-2012

Albireo Pharma licences Ajimoto rights to elobixibat in Japan, South Korea, Thailand, Indonesia, Vietnam and Taiwan.Elobixibat is a first-in-class investigational drug in development for chronic constipation and irritable bowel syndrome with constipation .Phase II trials have been promising.

Related News

Related Gastroenterology Information

Related Gastroenterology Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013